First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 720 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Visits to Online Breast Cancer Communities Could Help Policy Makers and... February 11, 2021 Few People with Cancer Undergo Testing for Inherited Gene Mutations August 1, 2023 Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows December 13, 2018 ESMO Congress 2023, 20-24 October 2023 Madrid, Spain October 6, 2023 Load more HOT NEWS Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients... Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Results in Greater EFS and pCR... ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology... Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others...
